Vetoquinol Past Earnings Performance
Past criteria checks 2/6
Vetoquinol has been growing earnings at an average annual rate of 14.8%, while the Pharmaceuticals industry saw earnings growing at 14% annually. Revenues have been growing at an average rate of 7.6% per year. Vetoquinol's return on equity is 8.7%, and it has net margins of 8.8%.
Key information
14.8%
Earnings growth rate
14.8%
EPS growth rate
Pharmaceuticals Industry Growth | 16.3% |
Revenue growth rate | 7.6% |
Return on equity | 8.7% |
Net Margin | 8.8% |
Next Earnings Update | 20 Mar 2025 |
Recent past performance updates
Recent updates
What Vetoquinol SA's (EPA:VETO) P/E Is Not Telling You
Nov 21Subdued Growth No Barrier To Vetoquinol SA's (EPA:VETO) Price
Aug 06Vetoquinol (EPA:VETO) Ticks All The Boxes When It Comes To Earnings Growth
Jul 13An Intrinsic Calculation For Vetoquinol SA (EPA:VETO) Suggests It's 40% Undervalued
Jun 15Why We're Not Concerned About Vetoquinol SA's (EPA:VETO) Share Price
May 01Here's What Analysts Are Forecasting For Vetoquinol SA (EPA:VETO) After Its Annual Results
Mar 24With EPS Growth And More, Vetoquinol (EPA:VETO) Makes An Interesting Case
Jan 13Vetoquinol SA (EPA:VETO) Shares Could Be 32% Below Their Intrinsic Value Estimate
Dec 19Vetoquinol (EPA:VETO) Seems To Use Debt Quite Sensibly
Nov 23Here's Why We Think Vetoquinol (EPA:VETO) Is Well Worth Watching
Oct 06Is Vetoquinol SA (EPA:VETO) Trading At A 45% Discount?
Sep 12Are Investors Undervaluing Vetoquinol SA (EPA:VETO) By 28%?
May 24Is Vetoquinol (EPA:VETO) Using Too Much Debt?
May 03Vetoquinol SA (EPA:VETO) Shares Could Be 22% Below Their Intrinsic Value Estimate
Jan 05Here's Why Vetoquinol (EPA:VETO) Has Caught The Eye Of Investors
Dec 01We Think Vetoquinol (EPA:VETO) Can Stay On Top Of Its Debt
Oct 07Vetoquinol SA (EPA:VETO) Shares Could Be 31% Below Their Intrinsic Value Estimate
Aug 19Do Vetoquinol's (EPA:VETO) Earnings Warrant Your Attention?
Jul 16Vetoquinol SA (EPA:VETO) Shares Could Be 29% Below Their Intrinsic Value Estimate
May 07I Ran A Stock Scan For Earnings Growth And Vetoquinol (EPA:VETO) Passed With Ease
Apr 06Calculating The Intrinsic Value Of Vetoquinol SA (EPA:VETO)
Dec 21Is Vetoquinol (EPA:VETO) Using Too Much Debt?
Nov 29Estimating The Intrinsic Value Of Vetoquinol SA (EPA:VETO)
Sep 10Is Vetoquinol (EPA:VETO) A Risky Investment?
Aug 01Is Vetoquinol SA (EPA:VETO) Trading At A 35% Discount?
May 12Vetoquinol SA's (EPA:VETO) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Feb 11A Look At The Intrinsic Value Of Vetoquinol SA (EPA:VETO)
Jan 20Vetoquinol (EPA:VETO) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Dec 29How Much Is Vetoquinol SA (EPA:VETO) Paying Its CEO?
Dec 09We Think Vetoquinol's (EPA:VETO) Statutory Profit Might Understate Its Earnings Potential
Nov 18Revenue & Expenses Breakdown
How Vetoquinol makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 537 | 47 | 187 | 0 |
31 Mar 24 | 533 | 51 | 185 | 0 |
31 Dec 23 | 529 | 56 | 183 | 0 |
30 Sep 23 | 527 | 57 | 182 | 0 |
30 Jun 23 | 525 | 59 | 181 | 0 |
31 Mar 23 | 533 | 53 | 179 | 0 |
31 Dec 22 | 540 | 48 | 178 | 0 |
30 Sep 22 | 538 | 48 | 180 | 0 |
30 Jun 22 | 537 | 48 | 182 | 0 |
31 Mar 22 | 529 | 55 | 179 | 0 |
31 Dec 21 | 521 | 63 | 176 | 0 |
30 Sep 21 | 504 | 52 | 165 | 0 |
30 Jun 21 | 487 | 40 | 154 | 0 |
31 Mar 21 | 457 | 30 | 151 | 0 |
31 Dec 20 | 427 | 19 | 147 | 0 |
30 Sep 20 | 418 | 25 | 145 | 0 |
30 Jun 20 | 408 | 31 | 143 | 0 |
31 Mar 20 | 402 | 30 | 141 | 0 |
31 Dec 19 | 396 | 29 | 139 | 0 |
30 Sep 19 | 385 | 31 | 139 | 0 |
30 Jun 19 | 374 | 33 | 139 | 0 |
31 Mar 19 | 371 | 35 | 137 | 0 |
31 Dec 18 | 368 | 36 | 135 | 0 |
30 Sep 18 | 360 | 36 | 133 | 0 |
30 Jun 18 | 352 | 36 | 131 | 0 |
31 Mar 18 | 352 | 36 | 130 | 0 |
31 Dec 17 | 352 | 35 | 130 | 0 |
30 Sep 17 | 354 | 32 | 129 | 0 |
30 Jun 17 | 356 | 29 | 127 | 0 |
31 Mar 17 | 353 | 28 | 126 | 0 |
31 Dec 16 | 350 | 28 | 124 | 0 |
30 Sep 16 | 349 | 27 | 124 | 0 |
30 Jun 16 | 348 | 25 | 124 | 0 |
31 Mar 16 | 345 | 25 | 123 | 0 |
31 Dec 15 | 343 | 24 | 122 | 0 |
30 Sep 15 | 338 | 26 | 120 | 0 |
30 Jun 15 | 333 | 28 | 118 | 0 |
31 Mar 15 | 324 | 27 | 115 | 0 |
31 Dec 14 | 315 | 26 | 113 | 0 |
30 Sep 14 | 309 | 25 | 110 | 0 |
30 Jun 14 | 304 | 24 | 108 | 0 |
31 Mar 14 | 302 | 24 | 107 | 0 |
Quality Earnings: VETO has high quality earnings.
Growing Profit Margin: VETO's current net profit margins (8.8%) are lower than last year (11.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VETO's earnings have grown by 14.8% per year over the past 5 years.
Accelerating Growth: VETO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: VETO had negative earnings growth (-19.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (5.2%).
Return on Equity
High ROE: VETO's Return on Equity (8.7%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/07 21:57 |
End of Day Share Price | 2025/02/07 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vetoquinol SA is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Carole Rozen | CA Cheuvreux |
Arnaud Cadart | CIC Market Solutions (ESN) |
Alexandre Letz | Gilbert Dupont |